The present disclosure relates to a novel compound for photodynamic therapy of cancer, a composition including the same, and a method for photodynamic therapy of cancer, and more specifically, a novel photosensitizer compound based on Nplmidazole having a C═S functional group introduced, a composition and sensor including the same and a method for photodynamic therapy using the same.

The present invention relates to metal complexes bearing at least one (E-E′)-4,4′-bisstyryl-2,2′-bipyridine ligand (LIG1) of the following formula (I): or a pharmaceutically acceptable salt and/or solvate thereof. The present invention also relates to pharmaceutical compositions comprising these complexes and at least one pharmaceutically acceptable excipient. The present invention also relates to the use of compounds of formula (I) or pharmaceutical compositions comprising thereof as drug and as photosensitizer agent in photodynamic therapy. The present invention relates to methods of preparation of said complexes.

##STR00001##

The present disclosure provides EBNA1 and LMP1 dual-targeting peptides and upconversion nanoparticles conjugates comprising the same useful as therapeutic and theranostic agents capable of targeting EBNA1 and LMP1 proteins present in Epstein-Barr virus infected cells, such as cancer.

An upconversion nanoparticle includes at least one host selected from LiYF.sub.4, NaY, NaYF.sub.4, NaGdF.sub.4, and CaF.sub.3, at least one sensitizer selected from Sm.sup.3+, Nd.sup.3+, Dy.sup.3+, Ho.sup.3+, and Yb.sup.3+ doped in the at least one host, and at least one activator selected from Er.sup.3+, Ho.sup.3+, Tm.sup.3+, and Eu.sup.3+ doped in the at least one host. The upconversion nanoparticle is designed using a calculation from first principles to absorb light in the near-infrared wavelength range whose stability is ensured. Further, a hyaluronic acid-upconversion nanoparticle conjugate, in which the upconversion nanoparticle as described above is bonded to hyaluronic acid, is provided to be used in various internal sites with a hyaluronic acid receptor, particularly enables targeting, and increases an internal retention period and biocompatibility thereof.

The present invention relates to methods for treating cell proliferation disorders comprising (1) administering to the subject at least one activatable pharmaceutical agent that is capable of activation by a simultaneous two photon absorption event and of effecting a predetermined cellular change when activated, (2) administering at least one plasmonics-active agent to the subject, and (3) applying an initiation energy from an initiation energy source to the subject, wherein the plasmonics-active agent enhances or modifies the applied initiation energy, such that the enhanced or modified initiation energy activates the activatable pharmaceutical agent by the simultaneous two photon absorption event in situ, thus causing the predetermined cellular change to occur, wherein said predetermined cellular change treats the cell proliferation related disorder, and the use of plasmonics enhanced photospectral therapy (PEPST) and exiton-plasmon enhanced phototherapy (EPEP) in the treatment of various cell proliferation disorders, and the PEPST and EPEP agents and probes.

A phosphor-containing drug activator and suspension thereof are provided. The suspension at least includes two or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays. The two or more phosphors include Zn2SiO4:M12+ and (3Ca3 (PO4)2Ca(F, Cl)2:Sb3*, Mn2+) at a ratio NP-200:GTP-4300 of from 1:10 to 10:1, and each of the two phosphors have an ethylene cellulose coating and/or a diamond-like carbon coating. The suspension further includes a pharmaceutically acceptable carrier. A system for treating a disease in a subject in need thereof includes a) the above-noted suspension, b) a photoactivatable drug containing 8-methoxypsoralen (8-MOP or UVADEX) untethered from the two or more phosphors, c) one or more devices which infuse the photoactivatable drug and the suspension including the pharmaceutically acceptable carrier into a diseased site in the subject, and d) an x-ray source which is controlled to deliver a dose of x-rays to the subject for production of the ultraviolet light.

Compositions are provided in which dendrimers and/or nanoparticles are synthesized with multi-photon responsive elements and self-immolative oligomers. The compositions may be utilized to selectively deliver Payloads within tissue by irradiating the compositions. The compositions may also be used to amplify sensitivity to irradiation.

An example antimicrobial treatment system includes an illumination system configured to deliver illumination that activates a photosensitizing agent applied to a cornea. The system also includes a controller configured to control the illumination system. The controller detects an ulcerative region on a cornea and causes the illumination system to deliver the illumination to activate the photosensitizing agent applied to the ulcerative region according to a set of parameters for treating the ulcerative region. The illumination is restricted to the ulcerative region, and activation of the photosensitizing agent in the ulcerative region generates an antimicrobial effect.

Provided are methods involving the use of biomarkers, in relation to photoimmunotherapy, such as photoimmunotherapy induced by activation of a phthalocyanine dye conjugated to a targeting molecule that binds a protein on tumor cell, for example, an IR700-antibody conjugate, and combination therapies, for example, that include photoimmunotherapy and an additional therapeutic agent, such as an immune modulating agent. In some aspects, the provided embodiments can be used to identify or select subjects for photoimmunotherapy and/or the combination therapy, or to assess the likelihood of response to photoimmunotherapy and/or to the additional therapeutic agents. Features of the methods and uses provide various advantages, such as improved efficacy. In some aspects, the provided embodiments can be used to provide personalized medicine and tailored therapy regimens for subjects. Also provided are therapeutic methods involving the use of biomarkers in the treatment of diseases and conditions, including tumors or cancers.

A composition includes a photon upconversion nanoparticle coupled to a photosensitizer nanoparticle that can absorb light and convert tissue oxygen into reactive oxygen species. A low temperature hydrothermal method of making photon upconversion nanoparticles includes dispersing Yb(NO.sub.3).sub.3, Y(NO.sub.3).sub.3, and Er(NO.sub.3).sub.3 in water to prepare a mixture; adding an ethylenediaminetetraacetic acid and NaF with sonication to make a solution; adjusting a pH of the solution to approximately 3.5 using HNO.sub.3 and NaOH; treating the solution hydrothermally at approximately 130° C. for approximately 4 hours; quenching to approximately 20° C.; collecting and washing the photon upconversion nanoparticles. A near infrared triggered photon upconversion method for synergistic photodynamic and photothermal cancer therapy includes administering a nanocomposite comprising a photon upconversion nanoparticle coupled to a photosensitizer nanoparticle that can absorb light and convert tissue oxygen into reactive oxygen species; and exposing the mammal and the nanocomposite to a near infrared source of actinic radiation.